BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ASP7317 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ASP7317\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03178149-11063@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:ASP7317: Phase 1 readout est. (NCT03178149)
DESCRIPTION:ASP7317\, phase 1\, Geographic Atrophy.\nStudy: A Study of the 
 Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their C
 lear\, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age
 -related Macular Degeneration\nEstimated primary completion: 31 December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/asp7317#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03178149
URL:https://assetmemo.bio/drug/asp7317#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
